Astrazeneca AB has disclosed bicyclic heteroaromatic compounds acting as transcriptional enhancer factor (TEAD) and TEAD-4 inhibitors reported to be useful for the treatment of cancer.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has finalized the protocol for a preclinical dose-ranging efficacy study of VTX-0P4, a protein-based cancer vaccine targeting prostate stem cell antigen (PSCA), a key target in the treatment of prostate cancer.
Polaris Pharmaceuticals Inc. has submitted the first part of its rolling BLA to the FDA for lead product, ADI-PEG 20, for systemic treatment of patients with malignant pleural mesothelioma with non-epithelioid histology in combination with a platinum agent and pemetrexed. The BLA is supported by the pivotal phase III Atomic study in which pegargiminase (pegylated arginine deiminase/ADI-PEG 20) met the primary endpoint of a statistically significant improvement in overall survival and the secondary endpoint of a significant improvement in progression-free survival in patients with malignant pleural mesothelioma.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.
Graviton Bioscience BV has described Rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, lung, cardiovascular, eye, inflammatory and neurological disorders.
Legochem Biosciences Inc. has synthesized Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, HIV infection, and hepatitis B virus infection.
Researchers from Apeximmune Therapeutics Inc. presented the discovery and preclinical evaluation of AIM-104, a novel potent pan-allele anti-SIRPα antibody for the treatment of cancer.
The U.S. and China biotech Apollomics Inc. on Nov. 16 gained the NMPA’s conditional approval for its cellular mesenchymal-epithelial transcription inhibitor for lung cancer called vebreltinib (APL-1010) through its Beijing-based partner, Avistone Biotechnology Co. Ltd.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections.
The U.S. and China biotech Apollomics Inc. on Nov. 16 gained the NMPA’s conditional approval for its cellular mesenchymal-epithelial transcription inhibitor for lung cancer called vebreltinib (APL-1010) through its Beijing-based partner, Avistone Biotechnology Co. Ltd.
RSS
